retatrutide clinical studies retatrutide for Sale in the US Eli Lilly infiltrates anti-obesity market

Hostetler More than 85% of obese participants with fatty liver disease in a clinical trial of the experimental drug retatrutide reduced their liver fat to the point where they would no longer be classified as having fatty liver disease, according to the Virginia Commonwealth University hepatologist leading the sub-study

A practical approach used in clinical trials for GLP-1 class-switches involves a two-week washout or, if the patient is medically stable, direct substitution starting at the lowest retatrutide titration dose (2 mg weekly in the phase 2 protocol) with dose escalation over 24 weeks [2]

This approach delivers hydration, electrolytes, and essential vitamins directly into your bloodstream, often providing quick relief from symptoms

FDA approval is expected in 2025-2026 if trials are successful

Tirzepatide (Zepbound): Up to 22.5% average weight loss